Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

1 Day NVO 1.88% DJIA 0.68% S&P 500 -0.03% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

What are the best new PC games in 2024? Perhaps you’ve just been paid, your bank account is filled with virtual dosh, or you simply want to get caught up with the latest PC games because they ...

Novo's new obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

O número de novos cassinos online presentes no Brasil não para de crescer. Com a indústria a todo o vapor, as opções aumentam consideravelmente e dão ao jogador total liberdade de escolha. Parimatch: ...

Entre os novos santos estão os 11 “mártires de Damasco”, mortos em julho de 1860 na capital síria durante o domínio otomano por um comando de drusos muçulmanos num mosteiro num bairro cristão. De ...

Feipet, evento que reúne profissionais dos setores pet e veterinário, segue até terça-feira em Novo Hamburgo ...